Table 1.

Univariate and multivariate analyses of clinicopathological characteristics and immune gene-based signature with overall survival in GBM cohorts.

Variable	Univariate analysis		Multivariate analysis
	HR (95 % CI)	P	HR (95 % CI)	P
TCGA (n = 137)
Age
>=60 vs. <60	1.62 (1.09–2.408)	0.017	1.398 (0.921–2.121)	0.116
Gender
Male vs. female	1.165 (0.783–1.735)	0.451
KPS
>=80 vs. <80	0.846 (0.519–1.379)	0.503
IDH status
Wild-type vs. mutation	4.544 (1.656–12.467)	0.003	2.444 (0.848–7.047)	0.098
MGMT methylation
Unmethylated vs. methylated	1.861 (1.23–2.815)	0.003	1.715 (1.125–2.613)	0.012
Risk score
High vs. low	3.107 (2.005–4.816)	<0.001	2.476 (1.581–3.878)	<0.001
CGGA RNA-seq (n = 105)
Age
>=60 vs. <60	1.99 (1.21–3.273)	0.007	1.657 (0.983–2.793)	0.058
Gender
Male vs. female	1.142 (0.744–1.752)	0.545
IDH status
Wild-type vs. mutation	1.082 (0.636–1.839)	0.772
MGMT methylation
Unmethylated vs. methylated	0.996 (0.654–1.518)	0.987
Chemotherapy
Yes vs. no	0.481 (0.303–0.765)	0.002	0.528 (0.33–0.845)	0.008
Radiotherapy
Yes vs. no	0.923 (0.511–1.669)	0.792
Risk score
High vs. low	1.896 (1.246–2.886)	0.003	1.644 (1.05–2.573)	0.03

Bold italics indicate statistically significant values (P <0.05).